Literature DB >> 31591609

A facile method for the synthesis of copper-cysteamine nanoparticles and study of ROS production for cancer treatment.

Nil Kanatha Pandey1, Lalit Chudal1, Jonathan Phan1, Liangwu Lin2, Omar Johnson1, Meiying Xing1, J Ping Liu1, Haibin Li3, Xuejing Huang1, Yang Shu4, Wei Chen1.   

Abstract

Copper-cysteamine (Cu-Cy) is a novel sensitizer that can be excited by ultraviolet (UV) light, microwave (MW), ultrasound, and X-rays to generate highly toxic reactive oxygen species (ROS) for cancer cell destruction. The purpose of this study is to present a facile method for the synthesis of Cu-Cy nanoparticles. Interestingly, we were able to decrease both the stirring and heating time by about 24 and 6 times, respectively, thus making Cu-Cy nanoparticles more economical than what was reported before. 1,4-Diazabicylo[2.2.2]octane (DABCO), a well-known singlet oxygen quencher, showed that the majority of ROS produced by Cu-Cy nanoparticles upon UV and MW exposure were singlet oxygen. Moreover, ROS generated by Cu-Cy nanoparticles upon UV and MW exposure were confirmed by a known ROS tracking agent, dihydrorhodamine 123, further serving as an additional piece of evidence that Cu-Cy is a promising ROS generating agent to destroy cancer cells as well as bacteria or viruses by a radical therapeutic approach. Additionally, for the first time, the hydroxyl radical (˙OH) produced by Cu-Cy nanoparticles upon MW activation was proved by a photoluminescence (PL) technique using coumarin as a probe molecule. Remarkably, newly synthesized nanoparticles were found to be much more effective for producing ROS and killing cancer cells, suggesting that the new method may have increased the reactivity of the Cu-Cy nanoparticles due to an overall size reduction. Overall, the new method not only reduced the synthesis time but also enhanced the effectiveness of Cu-Cy nanoparticles for photodynamic therapy.

Entities:  

Year:  2019        PMID: 31591609     DOI: 10.1039/c9tb01566c

Source DB:  PubMed          Journal:  J Mater Chem B        ISSN: 2050-750X            Impact factor:   6.331


  6 in total

1.  Combination of Disulfiram and Copper-Cysteamine Nanoparticles for an Enhanced Antitumor Effect on Esophageal Cancer.

Authors:  Yan Chang; Fang Wu; Nil Kanatha Pandey; Lalit Chudal; Meiying Xing; Xiaoli Zhang; Linh Nguyen; Xian Liu; J Ping Liu; Wei Chen; Zui Pan
Journal:  ACS Appl Bio Mater       Date:  2020-09-09

2.  A powerful combination of copper-cysteamine nanoparticles with potassium iodide for bacterial destruction.

Authors:  Xiumei Zhen; Lalit Chudal; Nil Kanatha Pandey; Jonathan Phan; Xin Ran; Eric Amador; Xuejing Huang; Omar Johnson; Yuping Ran; Wei Chen; Michael R Hamblin; Liyi Huang
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2020-01-11       Impact factor: 7.328

3.  Effects of Nanoparticle Size and Radiation Energy on Copper-Cysteamine Nanoparticles for X-ray Induced Photodynamic Therapy.

Authors:  Bindeshwar Sah; Jing Wu; Adam Vanasse; Nil Kanatha Pandey; Lalit Chudal; Zhenzhen Huang; Wenzhi Song; Hongmei Yu; Lun Ma; Wei Chen; Michael P Antosh
Journal:  Nanomaterials (Basel)       Date:  2020-06-01       Impact factor: 5.076

4.  Fabrication of Anisotropic Cu Ferrite-Polymer Core-Shell Nanoparticles for Photodynamic Ablation of Cervical Cancer Cells.

Authors:  Shuo-Hsiu Kuo; Po-Ting Wu; Jing-Yin Huang; Chin-Pao Chiu; Jiashing Yu; Mei-Yi Liao
Journal:  Nanomaterials (Basel)       Date:  2020-12-04       Impact factor: 5.076

Review 5.  Colorectal liver metastasis: molecular mechanism and interventional therapy.

Authors:  Hui Zhou; Zhongtao Liu; Yongxiang Wang; Xiaoyong Wen; Eric H Amador; Liqin Yuan; Xin Ran; Li Xiong; Yuping Ran; Wei Chen; Yu Wen
Journal:  Signal Transduct Target Ther       Date:  2022-03-04

Review 6.  Polymer-Based Hybrid Nanoarchitectures for Cancer Therapy Applications.

Authors:  Arun Kumar; Mirkomil Sharipov; Abbaskhan Turaev; Shavkatjon Azizov; Ismatdjan Azizov; Edwin Makhado; Abbas Rahdar; Deepak Kumar; Sadanand Pandey
Journal:  Polymers (Basel)       Date:  2022-07-26       Impact factor: 4.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.